ISRCTN62568875已完成不适用
Evaluation of the gut absorption rate of glucose during an evening meal and breakfast: a prospective three-centre observational cohort study in pregnant women with type 1 diabetes
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge (UK)0 个研究点目标入组 12 人开始时间: 2009年10月7日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. Signed informed consent obtained before study-related activities. Study-related activities are any procedure that would not have been performed during standard medical care.
- •2. The participant is between 16 and 44 years of age (inclusive)
- •3. The participant has type 1 diabetes, as defined by World Health Organization (WHO) for at least 12 months and has had a viable singleton pregnancy confirmed by ultrasound
- •4. The participant has been on insulin pump or multiple daily injection (MDI) therapy for at least 6 months
- •5. The participant is able and willing to use a real time continuous sensor
排除标准
- •1. Non-type 1 diabetes mellitus including those secondary to chronic disease
- •2. Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results such as coeliac disease or untreated hypothyroidism
- •3. Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and monoamine oxidase (MAO) inhibitors
- •4. Known or suspected allergy against insulin
- •5. Women with clinically significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator
- •6. Documented gastroparesis
- •7. Very poor glycaemic control i.e. HbA1c greater than or equal to 10%
- •8. Significant obesity, i.e., body mass index (BMI) at booking greater than 35 kg/m^2
- •9. Total daily insulin dose greater than 1.5 IU/kg at booking
- •10. Women who have conceived with in-vitro fertilisation (IVF) or assisted reproductive techniques
研究者
相似试验
已完成
Unknown
Verifying the control effects of glucose absorption through the comparison of SekirenB2 with a placebo in double blind cross over comparative study.1)HbA1c: 6.4% or less2)HbA1c: 6.5% or more and less than 7.0%JPRN-jRCT1091220179ADAPTGEN PHARMACEUTICAL CO.,LTD.20
已完成
不适用
Verifying the control effects of glucose absorption through the comparison of SekirenB2 with a placebo in double blind cross over comparative study.Healthy individualJPRN-UMIN000014000ADAPTGEN PHARMACEUTICAL CO.,LTD.20
已完成
不适用
Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR enterography in patients not taking metformitype 2 diabetes mellitusJPRN-UMIN000045137Kobe university5
尚未招募
不适用
Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR enterography in patients taking imeglimitype 2 diabetes mellitusJPRN-UMIN000045345Kobe university5
尚未招募
Unknown
Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR Enterography in patients taking imeglimitype 2 diabetes mellitusJPRN-UMIN000049426Kobe University10
